STOCK TITAN

Bolt Biotherapeutics, Inc. - $BOLT STOCK NEWS

Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: $BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.

Bolt Biotherapeutics, Inc. (BOLT) is a clinical-stage biopharmaceutical company specializing in novel immunotherapies for cancer treatment. Originating from Dr. Engleman's lab at Stanford University, the company leverages groundbreaking technology to develop tumor-targeted therapies, capitalizing on the combined power of the innate and adaptive immune systems. Backed by top-tier life sciences investors, Bolt is on a promising growth trajectory, dedicated to bringing innovative and curative therapies to patients.

The company’s proprietary Boltbody™ ISAC (Immune-Stimulating Antibody Conjugate) platform is the cornerstone of its therapeutic pipeline, which includes candidates like BDC-1001 and BDC-3042. This platform merges tumor-targeting antibodies with immune-stimulating linker-payloads designed to reprogram the tumor microenvironment, fostering a robust anti-cancer response.

BDC-1001 targets HER2-positive cancers and has shown durable clinical responses and a favorable safety profile in Phase 1 trials. Notably, the FDA granted Orphan Drug Designation to BDC-1001 for gastric cancer treatment, underlining its potential to address unmet medical needs. Phase 2 trials are underway for various cancers, including breast, colorectal, and endometrial cancers.

BDC-3042 targets Dectin-2, a receptor expressed by tumor-associated macrophages (TAMs), and aims to convert these cells from tumor-supportive to tumor-destructive. Having received FDA clearance for its Investigational New Drug (IND) application, BDC-3042 is set to enter Phase 1 trials.

Bolt's pipeline also includes multiple Boltbody ISAC collaboration programs with leading biopharmaceutical companies, further validating its platform technology. The company’s financial health is robust, with strategic plans to fund ongoing and future clinical programs.

For more information, visit Bolt Biotherapeutics, Inc. website.

Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT) announced its Q1 2024 financial results, revealing a strategic pipeline prioritization and leadership changes. The company will focus on its Phase 1 Dectin-2 agonist antibody BDC-3042 and its next-gen Boltbody™ ISAC platform, including the new clinical candidate BDC-4182 targeting Claudin 18.2. Development of trastuzumab imbotolimod (BDC-1001) will halt, and the workforce will be cut by approximately 50% to extend the cash runway into the second half of 2026.

Willie Quinn replaces Randall Schatzman as CEO, with other leadership promotions announced. Financially, Bolt reported collaboration revenue of $5.3 million, up from $1.8 million in Q1 2023, and a loss from operations of $17.1 million, down from $18.4 million the previous year. R&D expenses increased to $16.5 million, driven by higher clinical trial costs. G&A expenses rose slightly to $5.8 million. The company will host a webcast to discuss these changes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.12%
Tags
management earnings
-
Rhea-AI Summary
Bolt Biotherapeutics (Nasdaq: BOLT) reports positive progress in Phase 2 studies for BDC-1001 and successful safety assessments for BDC-3042. The company's cash balance of $128.6 million as of December 31, 2023, is expected to fund key milestones through late 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
-
Rhea-AI Summary
Bolt Biotherapeutics (Nasdaq: BOLT) to present company overview at TD Cowen 44th Annual Healthcare Conference, offering insights into novel cancer immunotherapies. The presentation will be live webcasted on Bolt's website with replays available for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
conferences
Rhea-AI Summary
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) announced the dosing of the first patient in the Phase 2 clinical trial investigating BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC), as a single agent and in combination with the HER2-targeting antibody pertuzumab. The trial aims to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of BDC-1001 in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan (Enhertu®). The addition of pertuzumab has been shown to improve anti-tumor efficacy in preclinical models, offering new treatment options for patients with HER2-positive breast cancer. A poster detailing the trial design and rationale will be presented at the 2023 San Antonio Breast Cancer Symposium on December 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
-
Rhea-AI Summary
BOLT: Bolt Biotherapeutics Reports Positive Clinical Data and Financial Results, Receives FDA Orphan Drug Designation for BDC-1001 in Gastric Cancers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
-
Rhea-AI Summary
Bolt Biotherapeutics (Nasdaq: BOLT) will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Nov. 14, 2023. The presentation will be available via live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences
Rhea-AI Summary
Bolt Biotherapeutics presents updated data from its Phase 1 dose-escalation trial of BDC-1001 at ESMO 2023 Congress. Improved efficacy observed with one complete response and two long-term stable diseases. BDC-1001 continues to be well tolerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.77%
Tags
-
Rhea-AI Summary
Bolt Biotherapeutics to present preclinical data on combination therapy at SITC 38th Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
conferences
-
Rhea-AI Summary
Bolt Biotherapeutics announces dosing of first patient in Phase 1/2 clinical study of BDC-3042 for the treatment of various cancers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
Rhea-AI Summary
Bolt Biotherapeutics receives FDA Orphan Drug Designation for BDC-1001 in gastric cancer, including gastroesophageal junction cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags

FAQ

What is Bolt Biotherapeutics, Inc.?

Bolt Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment.

What is the Boltbody™ ISAC platform?

The Boltbody™ ISAC platform combines tumor-targeting antibodies with immune-stimulating linker-payloads to reprogram the tumor microenvironment and generate an anti-cancer response.

What are BDC-1001 and BDC-3042?

BDC-1001 is a HER2-targeting ISAC in Phase 2 trials for various cancers, and BDC-3042 is a myeloid-modulating antibody targeting Dectin-2, entering Phase 1 trials.

What recent achievements has Bolt Biotherapeutics made?

Recent achievements include FDA Orphan Drug Designation for BDC-1001 for gastric cancer and positive Phase 1 results for BDC-1001.

Who backs Bolt Biotherapeutics?

Bolt Biotherapeutics is backed by top-tier life sciences investors and originated from Dr. Engleman’s lab at Stanford University.

What is the significance of Orphan Drug Designation for BDC-1001?

The Orphan Drug Designation for BDC-1001 highlights its potential to address unmet needs in treating rare cancers like gastric cancer.

What are the goals of the BDC-3042 program?

The goal of the BDC-3042 program is to repolarize tumor-associated macrophages from tumor-supportive to tumor-destructive cells.

What partnerships does Bolt Biotherapeutics have?

Bolt Biotherapeutics has multiple Boltbody ISAC collaboration programs with leading biopharmaceutical companies to advance its technology.

How is Bolt Biotherapeutics advancing its clinical programs?

Bolt Biotherapeutics continues to progress its clinical programs, with Phase 2 trials for BDC-1001 and upcoming Phase 1 trials for BDC-3042.

Where can I find more information about Bolt Biotherapeutics?

For more information, visit Bolt Biotherapeutics' official website at https://www.boltbio.com/.

Bolt Biotherapeutics, Inc.

Nasdaq:BOLT

BOLT Rankings

BOLT Stock Data

28.59M
21.43M
3.47%
64.19%
5.59%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY